Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study

Alessandro Passardi, Emanuela Scarpi, Elisa Neri, Elisabetta Parisi, Giulia Ghigi, Giorgio Ercolani, Andrea Gardini, Giuliano La Barba, Flavia Pagan, Andrea Casadei-Gardini, Martina Valgiusti, Fabio Ferroni, Giovanni Luca Frassineti, Antonino Romeo

Research output: Contribution to journalArticlepeer-review


The aim of the study was to evaluate the safety and efficacy of a new chemo-radiotherapy regimen for patients with locally advanced pancreatic cancer (LAPC). Patients were treated as follows: gemcitabine 1000 mg/m2 on day 1, and oxaliplatin 100 mg/m2 on day 2, every two weeks (GEMOX regimen) for 4 cycles, 15 days off, hypofractionated radiotherapy (35 Gy in 7 fractions in 9 consecutive days), 15 days off, 4 additional cycles of GEMOX, restaging. From April 2011 to August 2016, a total of 42 patients with non resectable LAPC were enrolled. Median age was 67 years (range 41–75). Radiotherapy was well tolerated and the most frequently encountered adverse events were mild to moderate nausea and vomiting, abdominal pain and fatigue. In total, 9 patients underwent surgical laparotomy (5 radical pancreatic resection 1 thermoablation and 3 explorative laparotomy), 1 patient became operable but refused surgery. The overall resectability rate was 25%, while the R0 resection rate was 12.5%. At a median follow-up of 50 months, the median progression-free survival and overall survival were 9.3 (95% CI 6.2–14.9) and 15.8 (95% CI 8.2–23.4) months, respectively. The results demonstrate the feasibility of a new chemo-radiotherapy regimen as a potential treatment for unresectable LAPC.

Original languageEnglish
Article number663
Issue number5
Publication statusPublished - May 2019


  • Neoadjuvant therapy
  • Pancreatic cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study'. Together they form a unique fingerprint.

Cite this